The thesis

AbbVie is a global biopharmaceutical company with a strong financial profile, showing 10.2% YoY revenue growth and 7148.0% gross margin. The company's conviction score is 21/100, indicating a medium conviction level. Analyst consensus is BUY, but the high P/E ratio of 72.1x raises valuation concerns. The company's extensive therapeutic portfolio is a key driver of its financial performance.

Why now

The current macro context, with inflation fears reigniting and the S&P 500 slipping, makes AbbVie's high valuation and revenue growth more critical to watch. The 10.2% YoY revenue growth is a key indicator of the company's ability to navigate the challenging healthcare landscape.

What to watch

Investors should watch AbbVie's upcoming revenue reports and any developments in its therapeutic portfolio, particularly the performance of HUMIRA. The company's ability to maintain its high gross margin of 7148.0% will also be a key indicator of its financial health.

Key risks

Drug pricing policy changes and trial failures are recurring shocks that could impact AbbVie's revenue growth and valuation. The high P/E ratio of 72.1x also poses a valuation risk if the company's growth slows down.

Theme exposure